alpha-aminopyridine has been researched along with Burkitt Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Ahn, KS; Go, J; Han, H; Hong, J; Kim, D; Koh, Y; Liu, J; Park, H; Park, J; Shin, DY; Yoon, SS | 1 |
1 review(s) available for alpha-aminopyridine and Burkitt Lymphoma
| Article | Year |
|---|---|
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
1 other study(ies) available for alpha-aminopyridine and Burkitt Lymphoma
| Article | Year |
|---|---|
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Topics: Aminopyridines; Benzamides; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Morpholines; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction | 2019 |